GANDEEVA
Live / Allowed — Notice of allowance issued (as of 04 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Jul 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97520558
- Mark type
- Stylized text
- Filed
- 26 Jul 2022
- Published for opposition
- 01 Aug 2023
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: Reagents for medical use; Pharmaceutical products for the treatment of cancer; Pharmaceutical preparations for the treatment of aberrant protein function; Antitumor drugs; chemotherapeutics; Pharmaceutical preparations for the treatment of cancer, neurological, inflammatory or metabolic diseases; Therapeutic agents for the treatment of cancer, neurological, inflammatory or metabolic diseases; Diagnostic biomarker reagents for medical purposes
Owner
- Gandeeva Therapeutics, Inc., Seattle, WA, US
- Gandeeva Therapeutics, Inc., Seattle, WA, US
Prosecution history
- 16 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 05 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Mar 2026 — CORRECTED NOA E-MAILED
- 05 Mar 2026 — DIVISIONAL PROCESSING COMPLETE
- 26 Sept 2025 — DIVISIONAL REQUEST RECEIVED
- 04 Mar 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Mar 2026 — SOU EXTENSION 4 GRANTED
- 26 Sept 2025 — SOU EXTENSION 4 FILED
- 26 Sept 2025 — TEAS STATEMENT OF USE RECEIVED
- 26 Sept 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 26 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Mar 2025 — SOU EXTENSION 3 GRANTED
- 25 Mar 2025 — SOU EXTENSION 3 FILED